Clark Capital Management Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Clark Capital Management Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.09M	Buy	+19,507	New	+$2.64M	0.02%	247
2025 Q2	–	Sell	-35,267	Closed	-$2.86M	–	477
2025 Q1	$2.86M	Buy	+35,267	New	+$3.15M	0.02%	242
2024 Q3	–	Sell	-46,488	Closed	-$4.31M	–	444
2024 Q2	$4.31M	Buy	+46,488	New	+$4.17M	0.03%	182
2023 Q3	–	Sell	-41,224	Closed	-$3.43M	–	378
2023 Q2	$3.43M	Buy	41,224 +269	+0.7%	+$22.5K	0.03%	191
2023 Q1	$3.12M	Sell	40,955 -24,797	-38%	-$2.06M	0.03%	188
2022 Q4	$5.46M	Buy	65,752 +1,181	+2%	+$95.6K	0.05%	170
2022 Q3	$5.12M	Sell	64,571 -5,444	-8%	-$459K	0.07%	166
2022 Q2	$5.2M	Buy	+70,015	New	+$5.26M	0.07%	162
2017 Q4	–	Sell	-14,509	Closed	-$1.26M	–	334
2017 Q3	$1.26M	Buy	+14,509	New	+$1.16M	0.04%	200

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Clark Capital Management Group's XBI Position: Q2 2026 in Review

Clark Capital Management Group opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 19,507 shares worth $3.09M. The stake represents 0.02% of the portfolio and ranks #247 among its holdings. This is a return to the name: Clark Capital Management Group previously reported a position in XBI as recently as Q1 2025.

Clark Capital Management Group first reported a position in XBI in Q3 2017 and has held it in 9 quarters since. The position peaked at $5.46M in Q4 2022. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Clark Capital Management Group held 19,507 shares of State Street SPDR S&P Biotech ETF worth $3.09M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Clark Capital Management Group position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.02% of Clark Capital Management Group's portfolio in Q2 2026, its #247 holding.
Clark Capital Management Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and has held it in 9 quarters since.
Clark Capital Management Group's State Street SPDR S&P Biotech ETF position peaked at $5.46M in Q4 2022.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.